Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Stay Informed: Medical and Research Updates
Connect With Us! Visit the Children's Corner for Macular Degeneration
 

 

Another BrightFocus-Funded Breakthrough on How Dry Age-Related Macular Degeneration Causes Blindness

Researchers identify inflammation proteins that kill retinal cells in miceā€”then block their action to prevent disease progression

May 2, 2012
Source: Cell

Findings: Advanced forms of dry age-related macular degeneration (AMD), called geographic atrophy, can lead to severe vision loss or blindness. Currently, there are no effective treatments for dry AMD (unlike wet AMD that has many treatment options). A team of researchers, including BrightFocus-funded Dr. Judit Baffi, has identified three “guilty parties” that can trigger the death of retinal pigmented epithelial (RPE) cells, which leads to blindness. It found that these three culprits—the NLRP3 Inflammasome, IL-18, and MyD88 proteins—could be prevented from killing the RPE cells in mice by using drugs or genetics techniques to block their activity.

Significance: This research is the continuation of a pivotal BrightFocus-funded discovery made last year by the same research team. It showed that uncontrolled buildup of a “junk” DNA product, called Alu RNA, can hijack the immune system to kill RPE cells. In this latest breakthrough, the team identified three culprits that participated in the hijacking and killing. Drugs targeted against these proteins may one day be the first treatment option for the hundreds of thousands of Americans with this vision-robbing, advanced form of dry AMD.

BrightFocus currently funds Dr. Judit Baffi, a pivotal member of this research team, for this research. Senior author on this paper, Dr. Jayakrishna Ambati and co-author, Dr. Joshua Dunaief, are former BrightFocus grantees.

This is the continuation of research on an important discovery reported in the journal, Nature, on February 6, 2011 by Dr. Baffi and colleagues.

 

View all news updates for macular degeneration


Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.

Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.

Twitter YouTube Facebook Shop for a Cause Pinterest Google+ Connect With Us